Chinese and Western Medicine Treatment of Myocardial Fibrosis Drugs

Overview

Journal Front Cardiovasc Med

Date 2025 Jan 30

PMID 39882321

Authors

Yuxi Zhu

Fangmei Zhang

Zhongcheng Li

Yu Zhou

Yi Shu

Jian Ruan

Guo Chen

Affiliations

Soon will be listed here.

Abstract

Myocardial fibrosis (MF) is a common pathological manifestation of many cardiovascular diseases, such as myocardial infarction, myocardial ischemia, and sudden cardiac death. It is characterized by excessive proliferation and activation of fibroblasts, transformation into myofibroblasts, and, eventually, excessive deposition of the extracellular matrix, resulting in heart damage. Currently, modern drugs such as angiotensin-converting enzyme inhibitors, diuretics, and β-blockers can improve myocardial fibrosis in clinical treatment, but their therapeutic effect on this disease is limited, with obvious side effects and high cost. Traditional Chinese medicine (TCM) has the advantages of multiple targets, low cost, and few side effects. Traditional Chinese medicines, such as Salvia miltiorrhiza, Astragalus, and Angelica extracts, and patent Chinese medicines, such as Qiliqiangxin capsules, Shenqi Yiqi dropping pills, and Tongxinluo capsules, can improve myocardial fibrosis. In this review, current Chinese and Western medicine methods for treating myocardial fibrosis are discussed. The signaling pathways and targets of Chinese and Western medicine are involved in the treatment of myocardial fibrosis. This review aimed to provide valuable insights and ideas for both clinical treatment and basic research on myocardial fibrosis.

References

Lu C, Yang Y, Lu Y, Zhu Y, Zhang A, Lyu S . Qishen Yiqi Dripping Pills for Cardiovascular Diseases: Effects and Mechanisms. Chin J Integr Med. 2022; 29(9):857-864. DOI: 10.1007/s11655-022-3288-2. View

Ma D, Xu T, Cai G, Wu X, Lei Z, Liu X . Effects of ivabradine hydrochloride combined with trimetazidine on myocardial fibrosis in rats with chronic heart failure. Exp Ther Med. 2019; 18(3):1639-1644. PMC: 6676191. DOI: 10.3892/etm.2019.7730. View

Chen T, Gudipudi R, Nguyen S, Carroll W, Clemmens C . Should Propranolol Remain the Gold Standard for Treatment of Infantile Hemangioma? A Systematic Review and Meta-Analysis of Propranolol Versus Atenolol. Ann Otol Rhinol Laryngol. 2022; 132(3):332-340. DOI: 10.1177/00034894221089758. View

Essawy A, Abd Elkader H, Khamiss O, Eweda S, Abdou H . Therapeutic effects of astragaloside IV and against bisphenol A-induced neurotoxicity and DNA damage in rats. PeerJ. 2021; 9:e11930. PMC: 8359804. DOI: 10.7717/peerj.11930. View

Zhou F, Wu T, Wang W, Cheng W, Wan S, Tian H . CMR-Verified Myocardial Fibrosis Is Associated With Subclinical Diastolic Dysfunction in Primary Aldosteronism Patients. Front Endocrinol (Lausanne). 2021; 12:672557. PMC: 8160454. DOI: 10.3389/fendo.2021.672557. View

Wang X, Yang J, Lu C, Hu Y, Xu Z, Wan Q . Qifu Yixin Formula Improves Heart Failure by Enhancing β-Arrestin2 Mediated the SUMOylation of SERCA2a. Drug Des Devel Ther. 2024; 18:781-799. PMC: 10946281. DOI: 10.2147/DDDT.S446324. View

Li S, Li S, Hao X, Zhang Y, Deng W . Perindopril and a Galectin-3 Inhibitor Improve Ischemic Heart Failure in Rabbits by Reducing Gal-3 Expression and Myocardial Fibrosis. Front Physiol. 2019; 10:267. PMC: 6438875. DOI: 10.3389/fphys.2019.00267. View

Zhang T, Wang X, Wang Z, Zhai J, He L, Wang Y . Canagliflozin Ameliorates Ventricular Remodeling through Apelin/Angiotensin-Converting Enzyme 2 Signaling in Heart Failure with Preserved Ejection Fraction Rats. Pharmacology. 2023; 108(5):478-491. DOI: 10.1159/000533277. View

Lopez B, Gonzalez A, Beaumont J, Querejeta R, Larman M, Diez J . Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol. 2007; 50(9):859-67. DOI: 10.1016/j.jacc.2007.04.080. View

10.

Huck D, Rosenberg M, Stauffer B . Nebivolol and incident cardiovascular events in hypertensive patients compared with nonvasodilatory beta blockers. J Hypertens. 2022; 40(5):1019-1029. DOI: 10.1097/HJH.0000000000003109. View

11.

Silva-Velasco D, Cervantes-Perez L, Sanchez-Mendoza A . ACE inhibitors and their interaction with systems and molecules involved in metabolism. Heliyon. 2024; 10(2):e24655. PMC: 10828069. DOI: 10.1016/j.heliyon.2024.e24655. View

12.

Wang J, Zou J, Shi Y, Zeng N, Guo D, Wang H . Traditional Chinese medicine and mitophagy: A novel approach for cardiovascular disease management. Phytomedicine. 2024; 128:155472. DOI: 10.1016/j.phymed.2024.155472. View

13.

Sacharczuk W, Dankowski R, Ozegowski S, Rojna M, Szyszka A . Evaluation of early left-sided cardiac reverse remodeling under combined therapy of sacubitril-valsartan and spironolactone compared with angiotensin-converting enzyme inhibitors and spironolactone. Front Cardiovasc Med. 2023; 10:1103688. PMC: 10106719. DOI: 10.3389/fcvm.2023.1103688. View

14.

Wu S, Da L, Xiao Q, Pan Q, Zhang J, Yang J . ASAP: a platform for gene functional analysis in Angelica sinensis. BMC Genomics. 2024; 25(1):96. PMC: 10804808. DOI: 10.1186/s12864-024-09971-z. View

15.

Safdar B, Mangi A . Survival of the Fittest: Impact of Cardiorespiratory Fitness on Outcomes in Men and Women with Cardiovascular Disease. Clin Ther. 2020; 42(3):385-392. DOI: 10.1016/j.clinthera.2020.01.014. View

16.

Connolly K, Batacan Jr R, Jackson D, Vella R, Fenning A . Perindopril prevents development of obesity and hypertension in middle aged diet-induced obese rat models of metabolic syndrome. Life Sci. 2022; 314:121291. DOI: 10.1016/j.lfs.2022.121291. View

17.

Zhen J, Bai J, Liu J, Men H, Yu H . Ginsenoside RG1-induced mesenchymal stem cells alleviate diabetic cardiomyopathy through secreting exosomal circNOTCH1 to promote macrophage M2 polarization. Phytother Res. 2023; 38(4):1745-1760. DOI: 10.1002/ptr.8018. View

18.

Wu N, Chi J, Cai H, Hu J, Lai Y, Lin C . Traditional Chinese medication qili qiangxin capsule protects against myocardial ischemia-reperfusion injury through suppressing autophagy via the phosphoinositide 3-kinase/protein kinase B/forkhead box O3 axis. J Ethnopharmacol. 2024; 337(Pt 1):118821. DOI: 10.1016/j.jep.2024.118821. View

19.

Wang M, Wang M, Zhao J, Xu H, Xi Y, Yang H . Dengzhan Shengmai capsule attenuates cardiac fibrosis in post-myocardial infarction rats by regulating LTBP2 and TGF-β1/Smad3 pathway. Phytomedicine. 2023; 116:154849. DOI: 10.1016/j.phymed.2023.154849. View

20.

Lyu Y, Huo J, Jiang W, Yang W, Wang S, Zhang S . Empagliflozin ameliorates cardiac dysfunction in heart failure mice via regulating mitochondrial dynamics. Eur J Pharmacol. 2023; 942:175531. DOI: 10.1016/j.ejphar.2023.175531. View